Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy

(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.

NCT Number	NCT07358130
Lead Sponsor	Kaohsiung Medical University Collaborators: Kaohsiung Veterans General Hospital.
Conditions	Helicobacter Pylori Infection
Enrollment	552 participants
Start Date	2025-10-21
Primary Completion	2027-11-15 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-22